Emerging roles of ADP-dependent glucokinase in prostate cancer.

This document discusses the emerging roles of ADP-dependent glucokinase (ADPGK) in prostate cancer (PCa). The standard clinical practice for treating advanced PCa is androgen deprivation therapy, but there is a need for novel therapeutic targets to improve treatment efficacy and patient survival. Glucose metabolism, particularly the Warburg effect, plays a key role in tumor progression. The study by Xu et al. identifies ADPGK as a crucial participant in PCa, with its upregulation correlating with adverse prognosis. ADPGK regulates PCa metabolic adaptability by interacting with aldolase C and activating AMP-activated protein kinase (AMPK) signaling. Targeting ADPGK shows potential for future drug development and clinical trials. ADPGK also promotes PCa cell migration and metastasis, making it a significant risk factor and promoter for PCa. The study provides unique perspectives on the involvement of ADPGK in PCa and may facilitate the development of innovative therapeutic approaches. ADPGK has also been reported to play essential roles in the regulation of immune cell activity, which could impact the comprehensive management of PCa. The complex of ADPGK and aldolase C promotes the phosphorylation of AMPK, suggesting a noncanonical kinase function of ADPGK. Overall, this research contributes to our understanding of PCa tumorigenesis and development and provides promising therapeutic targets for future treatment. [Extracted from the article]